Navidea inks China commercialization deal

Navidea Biopharmaceuticals (NYSEMKT:NAVB) enters into an exclusive agreement with a wholly-owned subsidiary of Hainan Sinotau Pharmaceutical Co., Ltd., to develop and commercialize Lymphoseek (technetium Tc 99m tilmanocept) Injection in China.

Under the terms of the agreement, Navidea will earn royalties on units sales, an upfront payment of $300K, up to $700K in development milestone payments and up to $1.5M in sales-related milestones.

Sinotau is responsible for funding and conducting clinical studies and regulatory submissions to the China Food and Drug Administration. It will be responsible for all sales and marketing activities post approval in China exclusive of Hong Kong, Macau and Taiwan.

From other sites
Comments (2)
  • pjg69ny
    , contributor
    Comments (436) | Send Message
    yippeee POS is 1.39 still after all these years, approvals, milestones, partnerships!!!!!!!!!!...
    4 Sep 2014, 01:27 PM Reply Like
  • 745
    , contributor
    Comments (388) | Send Message
    pjg, is your abbreviation for, Piece of &@!? or Point of Sale. Ha! Just double down and the Chinese will boost the price. Me? Think I'll dump the Piece of &@!?.
    4 Sep 2014, 03:29 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs